Cocrystal Pharma reports CC-42344 active against avian H5N1 PB2; Phase 2a results expected H2 2024

Cocrystal Pharma, Inc.

In vitro studies show CC-42344 inhibits the PB2 protein of avian influenza A (H5N1) strain from infected dairy cattle.
Phase 2a clinical trial of oral CC-42344 in influenza A subjects ongoing; topline results expected in second half of 2024.
CC-42344 binds to highly conserved PB2 region; high barrier to resistance and broad-spectrum activity highlighted.
CDC reports first human H5N1 cases from dairy cows; company notes no FDA-approved vaccine for humans against this strain.
Positive Phase 1 safety/tolerability data reported in 2022; structure-based platform used to confirm binding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.